Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Loma Linda University
Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
Patients must sign and give written informed consent in accordance with institutional and federal guidelines
You may not be if
Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
Clareo Health | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
